RNF4-dependent oncogene activation by protein stabilization by Thomas, J.J. et al.
ArticleRNF4-Dependent Oncogene Activation by Protein
StabilizationGraphical AbstractHighlightsd RNF4 stabilizes and enhances the activity of short-lived
oncogenes
d Stabilization requires substrate phosphorylation and atypical
ubiquitylation
d RNF4 is essential for cancer cell survival
d High RNF4 levels are correlated with reduced survival in
epithelial tumorsThomas et al., 2016, Cell Reports 16, 3388–3400
September 20, 2016 ª 2016 The Author(s).
http://dx.doi.org/10.1016/j.celrep.2016.08.024Authors
Jane J. Thomas, Mona Abed, Julian
Heuberger, ..., Walter Birchmeier, Alan L.
Schwartz, Amir Orian
Correspondence
mdoryan@techunix.technion.ac.il
In Brief
Ubiquitylation targets many oncogenes
for degradation. Thomas et al. show that
ubiquitylation by RNF4 stabilizes and
enhances the activity of key oncogenes.
RNF4 translates transient
phosphorylation signal(s) into long-term
protein stabilization, potentiating
oncogenic signaling and the tumor
phenotype. High RNF4 levels in epithelial
cancers are correlated with poor survival.
Cell Reports
ArticleRNF4-Dependent Oncogene Activation
by Protein Stabilization
Jane J. Thomas,1,9 Mona Abed,1,9,10 Julian Heuberger,3,9 Rostislav Novak,1,2 Yaniv Zohar,1,2 Angela P. Beltran Lopez,4
Julie S. Trausch-Azar,5 Ma. Xenia G. Ilagan,7 David Benhamou,1 Gunnar Dittmar,3 Raphael Kopan,8 Walter Birchmeier,3
Alan L. Schwartz,5,6 and Amir Orian1,11,*
1Rappaport Research Institute and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel
2Rambam Medical Center, Haifa 31096, Israel
3Max Delbr€uck Center for Molecular Medicine (MDC) in the Helmholtz Society, 13125 Berlin, Germany
4Instituto de Biotecnologia, Universidad Nacional de Colombia, Bogota D.C. 11132, Colombia
5Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA
6Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO 63110, USA
7Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA
8Division of Developmental Biology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati,
OH 45229, USA
9Co-first author
10Present address: Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
11Lead contact
*Correspondence: mdoryan@techunix.technion.ac.il
http://dx.doi.org/10.1016/j.celrep.2016.08.024SUMMARY
Ubiquitylation regulates signaling pathways critical
for cancer development and, in many cases, targets
proteins for degradation. Here, we report that ubiq-
uitylation by RNF4 stabilizes otherwise short-lived
oncogenic transcription factors, including b-catenin,
Myc, c-Jun, and the Notch intracellular-domain
(N-ICD) protein. RNF4 enhances the transcrip-
tional activity of these factors, as well as Wnt- and
Notch-dependent gene expression. While RNF4 is a
SUMO-targeted ubiquitin ligase, protein stabilization
requires the substrate’s phosphorylation, rather than
SUMOylation, and binding to RNF4’s arginine-rich
motif domain. Stabilization also involves generation
of unusual polyubiquitin chains and docking of
RNF4 to chromatin. Biologically, RNF4 enhances
the tumor phenotype and is essential for cancer cell
survival. High levels of RNF4 mRNA correlate with
poor survival of a subgroup of breast cancer pa-
tients, and RNF4 protein levels are elevated in 30%
of human colon adenocarcinomas. Thus, RNF4-
dependent ubiquitylation translates transient phos-
phorylation signal(s) into long-term protein stabiliza-
tion, resulting in enhanced oncoprotein activation.INTRODUCTION
Post-transcriptional modifications of nuclear oncoproteins play
important roles in cancer. Many oncogenic transcription factors
are phosphorylated by mitogenic signaling pathways that
enhance their activity. In addition, modifications by ubiquitin3388 Cell Reports 16, 3388–3400, September 20, 2016 ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://and ubiquitin-like proteins, such as small ubiquitin-like modifier
(SUMO), regulate critical signaling pathways, as well as tran-
scription factors (Bassermann et al., 2014; Flotho and Melchior,
2013; Swatek and Komander, 2016). In many cases, phosphor-
ylation primes the protein for ubiquitylation, which often results in
its degradation and loss of oncogenic activity (Lo´pez-Otı´n and
Hunter, 2010). Understanding how post-transcriptional modifi-
cations like phosphorylation, ubiquitylation, and SUMOylation
are connected and act in concert to regulate transcriptional
activity is an area of active research.
One such connector is the RING ubiquitin ligase RNF4, a
SUMO-targeted ubiquitin ligase (STUbL) (Sriramachandran
and Dohmen, 2014). STUbLs are conserved in evolution and
detected in yeast, flies, and mammals, and two members
RNF4 and RNF111 exist in vertebrates. STUbLs directly con-
nect the SUMO and the ubiquitin pathways: STUbLs bind to
SUMOylated chain(s) of target proteins via their SUMO-inter-
acting motifs (SIMs) then ubiquitylate these proteins, which
often results in their subsequent proteasomal degradation.
Moreover, STUbL-mediated ubiquitylation does not only target
proteins for degradation. For example, STUbL-mediated ubiq-
uitylation affects the affinity of protein-protein interactions,
which, in turn, affects subcellular localization, as well as en-
hances transcriptional activation (Fryrear et al., 2012; Poukka
et al., 2000; Hu et al., 2010). Previously, we showed that Dgrn,
the soleDrosophila STUbL protein, inactivates the SUMOylated
co-repressor Groucho/Transducing-like enhancer of split (Gro/
TLE) and inhibits Gro-dependent gene repression in vivo (Abed
et al., 2011).
Gro/TLE proteins inhibit signal-dependent transcription (i.e.,
Wnt/b-catenin signaling) in development and cancer (Cinnamon
and Paroush, 2008). The key co-activator of the Wnt pathway,
b-catenin, is usually unstable, and phosphorylation by GSK-3
targets b-catenin for proteasomal degradation. Following Wnt
pathway activation, cytoplasmic b-catenin is stabilized anduthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. RNF4 Enhances Transcriptional Activity of the Wnt/b-Catenin Pathway
(A) Schematic diagram of Wnt target gene activation by displacement of the co-repressor TLE by b-catenin. TRE, TCF-responsive element. Data shown are
mean ± SE from three independent experiments performed in triplicate.
(B and C) Wnt/b-catenin-luciferase reporter assays in HEK293T cells transfected with the indicated plasmids, and western blot analyses of indicated proteins in
extract used in these assays. RNF4, but not the RNF4 RING mutant (hRNF4C159A), alleviates TLE1-mediated repression of b-catenin-induced activation of the
TOPFLASH reporter (B). Enhancement of transcription by RNF4 requires its RING domain, but not its SIM, motifs (C).
(D) Western blot analysis of RNF4 protein levels. Upper: HEK293T cells were transfected with HA-RNF4 cDNA and infected with two independent constitutive
RNF4 shRNAs (C1, C2) or a scrambled control (sc-shRNA). Vertical black lines indicate two non-relevant lanes omitted. Middle: endogenous RNF4 protein level in
HCT116 colon cancer cells infected with either sc and shRNF4 (C1) coding lentiviral vectors used in (E). Lower: similar analyses of endogenous RNF4 protein in
MDA-1833 breast cancer cells used in (F).
(E and F) qPCR analysis of endogenous Axin2 mRNA transcripts levels following activation of Wnt signaling in the presence or absence of RNF4 shRNA.
Data shown are mean ± SE from three independent experiments. Axin2mRNA transcripts in HCT116 colon cancer cells infected with the indicated shRNAs with
or without Wnt3a treatment for four hours (E). Axin2 mRNA transcripts of MDA-1833 breast cancer cells without or with a 4-hr incubation with the GSK-inhibitor
Chir-99021 (2.5 mM) (F).translocates to the nucleus. Subsequently, nuclear b-catenin
displaces the co-repressor Gro/TLE from TCF4, which results
in activation of TCF4/b-catenin target genes, including Axin2
and c-Myc (Figure 1A; Holland et al., 2013; Clevers et al.,
2014). Moreover, RNF4 is a direct c-Myc target, and its expres-
sion is dependent on Wnt/b-catenin activity (Dutta-Simmons
et al., 2009; Reymann and Borlak, 2008).
Our observations that STUbLs antagonize Gro/TLE (Abed
et al., 2011; Barry et al., 2011) prompted us to determine whether
RNF4 plays a role in Wnt signaling. Here, we show that RNF4 en-
hances Wnt signaling by antagonizing TLE1 and concomitantly
stabilizing b-catenin protein. In addition, RNF4 stabilizes otherphosphorylated nuclear oncoproteins, including c-Myc, NICD,
c-Jun, and PGC1a. RNF4-mediated oncogene stabilization re-
quires binding of RNF4 to its substrates in their phosphorylated
forms. This activity of RNF4 is highly relevant to cancer; RNF4 is
a positive feedback enhancer of Wnt- and Notch-dependent
gene expression. It is essential for cancer cell survival, and its
expression potentiates tumorigenic properties of cancer cells.
High RNF4 mRNA levels correlate with poor survival of a sub-
group of breast cancer patients, and RNF4 protein levels were
elevated in 30% of human biopsies of colon adenocarcinoma,
but not in biopsies of normal colon or adenomas, suggesting a
role for RNF4 in tumor progression.Cell Reports 16, 3388–3400, September 20, 2016 3389
RESULTS
RNF4 Enhances Wnt/b-Catenin-Dependent
Transcriptional Activity
In Drosophila, the RNF4 ortholog Degringolade (Dgrn) antago-
nizes Groucho-dependent transcriptional repression (Abed
et al., 2011). Groucho, and its vertebrate ortholog TLE1, are
potent inhibitors of Wnt-dependent transcriptional activation
(Levanon et al., 1998). Therefore, we tested whether RNF4 re-
lieves TLE1-mediated repression of the Wnt luciferase reporter
TOPFLASH in HEK293T cells (TOP; Figure 1A; Levanon et al.,
1998; van de Wetering et al., 1991). Transfected TLE1 sup-
pressed b-catenin-induced activation of the TOP reporter. Co-
expression of RNF4, but not the mutant RNF4C159A which lacks
ubiquitylation activity, alleviated this repression and enhanced
transcriptional activation (Figure 1B). RNF4 enhanced both
TCF/b-catenin and LiCl-induced transcriptional activation, and
this was observed in the presence and absence of transfected
(exogenous) TLE1 (Figures 1C and S1A). RNF4 also enhanced
transcriptional activation induced by b-cateninY33A, a constitu-
tively active oncogenic form of b-catenin (Figure S1B; Morin
et al., 1997). This potentiation of transcriptional activation by
RNF4 depends on the binding of the TCF/b-catenin activation
complex to DNA, as RNF4 had no impact on a reporter that lacks
TCF binding sites (FOPFLASH; FOP), suggesting that RNF4 does
not affect the general transcriptional machinery in the absence of
the activation complexes (Figure S1C).
Next, we determined whether endogenous RNF4 is required
for the transcriptional activation ofWnt3a/b-catenin target genes
in various cancer cell lines. Constitutive RNF4 small hairpin
RNAs (shRNAs) (shRNF4-C1, shRNF4-C2), but not control (sc-
shRNA), efficiently reduced RNF4 mRNA and endogenous pro-
tein levels in MDA-1833 breast cancer cells and HCT116 colon
carcinoma cells (Figures 1D, S1D, and S1E). We analyzed the
expression of endogenous Axin2mRNA, a direct Wnt3a/b-cate-
nin target and a transcriptional readout for the pathway (Heu-
berger et al., 2014). In HCT116 colon carcinoma cells, RNF4
knockdown reduced Axin2 mRNA expression four hours after
Wnt3a treatment, as well as in the basal state (Figure 1E). We
observed a similar effect in MDA-1833 breast cancer cells where
we activated b-catenin-dependent transcription by addition of
the GSK-3 inhibitor Chir99021 (Figure 1F). RNF4 knockdown in
HEK293T cells, which express low endogenous RNF4 levels,
resulted in a modest, yet statistically significant, decrease in
TOP-luciferase activity (Figures 1D and S1F).
RNF4 Stabilizes and Binds to Phosphorylated b-Catenin
and c-Myc
While monitoring protein levels in the cells used in the reporter
assays above, we noticed that RNF4-expressing cells had higher
levels of b-catenin and its target c-Myc. We found that RNF4
expression increased the levels of b-catenin and endogenous
c-Myc proteins, and this required RNF4’s catalytic activity (Fig-
ures 1B and 1C). RNF4-dependent increase in endogenous
c-Myc protein was also observed in cells that do not overexpress
b-catenin (Figure 2A). It was also detected when c-Myc expres-
sion was driven by an exogenous CMV promoter, (i.e., not
dependent on the endogenous c-Myc promoter; Figure 2B).3390 Cell Reports 16, 3388–3400, September 20, 2016This function is conserved in evolution and co-expression of
Drosophila melanogaster, Rattus norvegicus, or Homo sapiens
RNF4 orthologs in HEK293T cells, all significantly elevated exog-
enous c-Myc protein levels (Figure 2B). Moreover, reduction of
RNF4 by two independent Doxycycline (Dox)-induced shRNF4s,
but not control shRNA (Renilla), caused a decrease in the protein
level of endogenous c-Myc in MDA-MB-231 cells (Figures 2C
and S1G). Elevated c-Myc level was due to protein stabilization,
as RNF4 stabilized HA-c-Myc in cycloheximide and 35S-methio-
nine-labeling pulse-chase experiments (Figures 2D and 2E).
RNF4 also stabilized other Myc protein family members such
as N-Myc and L-Myc (Figure S2A; data not shown).
c-Myc protein activity and stability are regulated by phosphor-
ylation: mitogenic signals mediated by multiple kinases such as
Erk/Mapk or Cdk2 phosphorylate Ser62 of c-Myc, which initially
stabilizes c-Myc and enhances its transcriptional activity (Sears
et al., 2000). Ser62 phosphorylation also primes c-Myc for
GSK3-dependent phosphorylation of Thr58 that subsequently
marks it for degradation (Welcker et al., 2004; Farrell and Sears,
2014). We observed that RNF4 stabilized p-Ser62 c-Myc in a
pronounced manner, using an antibody specific for singly phos-
phorylated p-Ser62 (Figure 2F). Similarly, reduction of RNF4 re-
sulted in a significant decrease in endogenous p-Ser62-c-Myc
protein level (Figure 2G). RNF4-dependent c-Myc stabilization
was abolished by mutation of S62A, but not T58A, in both
steady-state and dynamic experiments (Figures 2H and 2I). Like-
wise, chemical inhibition of kinases known to phosphorylate
Ser62 impaired the ability of RNF4 to stabilize c-Myc (Figure 2J).
In agreement, we observed that glutathione S-transferase
(GST)-fused RNF4 binds to phosphorylated 35S-Met-labeled
c-Myc in vitro. This binding was greatly reduced when we used
the non-phosphorylatable 35S-Met-c-MycS62A mutant, which
was also not stabilized by RNF4 (Figures 2H, 2I, and 3A). Like-
wise, pre-treatment of c-Myc with calf intestinal phosphatase
(CIP) abolished RNF4-binding (Figures 3B and S2B). Further-
more, c-Myc was highly ubiquitylated by RNF4 in cells and in a
cell-free ubiquitylation system (Figures 3C and S3A). In contrast,
the c-MycS62A mutant was poorly ubiquitylated (Figure 3C, up-
per). Moreover, we found that RNF4 stabilizes Ser45 phosphor-
ylated b-catenin. Similar to the case of Ser62-c-Myc, phosphor-
ylation of Ser45 within b-catenin enhances its activity (Maher
et al., 2010), but also primes b-catenin for GSK-dependent phos-
phorylation and degradation (Amit et al., 2002). We found that
RNF4 is required for maintaining endogenous b-catenin protein
level, and that phosphorylation of b-catenin Ser45 is required
for stabilization, binding, and ubiquitylation of b-catenin by
RNF4 (Figures 3D–3G, S2C, and S2D). Taken together, these
data suggest that RNF4 binds to p-Ser62-c-Myc and p-Ser45-
b-catenin, and targets each for ubiquitylation, which in turn leads
to their stabilization.
RNF4’s ARM Domain and Atypical Polyubiquitin Chains
Are Required for c-Myc and b-Catenin Stabilization
To understand how RNF4 interacts directly with its substrates,
we defined the structural motifs within RNF4 that recognize
phosphorylated c-Myc and b-catenin. RNF4’s short arginine-
rich motif (ARM; aa residues 72–82), along with its SIM domains,
were recently shown to recognize the phosphorylated and
Figure 2. RNF4 Stabilizes p-Ser62 c-Myc
(A) Endogenous c-Myc levels in HEK239T cells expressing plasmids coding for GFP (‘‘’’) or human RNF4.
(B) Steady-state levels of exogenous c-Myc protein in cells overexpressing GFP (lane 1) or rat, human, or Drosophila melanogaster RNF4 orthologs (lanes 2–4,
respectively).
(C) Endogenous c-Myc and RNF4 protein levels are reduced following expression of doxycycline-induced (200 ng/ml) shRNF4 (Sh1Dox, Sh2Dox), but not control
shRNA (Renilla). Actin serves as loading control.
(D) Cycloheximide (CHX)-chase for the indicated times, followed by western blot of HEK293T cells expressing HA-c-Myc, and the indicated RNF4 coding
plasmids.
(E) 35S-Met pulse-chase analysis of exogenous c-Myc in HEK293T cells. Expression of rRNF4, but not of the RING mutant rRNF4CS1, stabilizes c-Myc protein
levels, while rRNF4DSIM expression partially stabilizes c-Myc levels.
(F and G) Phosphorylation of Ser62-c-Myc is required for its stabilization by RNF4. CHX-chase for the indicated times, followed by western blot analysis using
pSer62 specific antibody (upper, CST #13748), or the 9E10 a-c-Myc antibody (middle) (F). Steady-state levels of endogenous proteins in extracts derived from
MD-MB 231 cells expressing shRNF4C1 or control (sc-shRNA) using a-pSer62-c-Myc, pan a-c-Myc (9E10), and a-RNF4 antibodies (G).
(H and I) Expression of the indicated plasmids in HEK293T cells, followed by western analysis. c-MycS62A is not stabilized by RNF4 in dynamic CHX-chase assay
(H). c-MycT58A, but not MycS62A, protein levels are stabilized by RNF4 at steady state (I).
(J) Chemical inhibition of kinases involved in Ser62-c-Myc phosphorylation impairs RNF4-dependent c-Myc stabilization. The level of indicated proteins was
determined using western blot analysis. Fold: relative change in c-Myc and p-Myc levels. Ux1, 7.5 mMU0126; Ux2, 15 mMU0126; PD, 10 mMPD98059, are MEK
inhibitors. LY, 10 mM LY2228820 is a MAP38 inhibitor; CVT, 10 mM CVT313 inhibits Cdk2.SUMOylated KAP1 protein (Figure 4A; Kuo et al., 2014). While
wild-type RNF4 stabilized c-Myc and b-catenin, the ARM dele-
tion mutant, RNF4DARM, failed to bind, ubiquitylate, or stabilize
these substrates (Figures 4B–4D, S2E, S4A, and S4B). Similarly,
a mutation in RNF4’s nucleosome-targeting region (NTR;
RNF4K179D), which mediates its interaction with nucleosomes,
failed to stabilize c-Myc or b-catenin (Figures 4A, 4C, and
4D; Groocock et al., 2014). In addition, both the ARM domainand K179 were required for RNF4-dependent enhancement of
b-catenin and c-Myc-dependent transcriptional activation (Fig-
ures 4C and 4D). In contrast, the SIM domains were not required
for binding to c-Myc (Figure S2F). Furthermore, expression of
the RNF4 SIM domain mutant, RNF4DSIM, which cannot bind to
SUMOylated proteins, enhanced b-catenin and c-Myc-depen-
dent transcriptional activation albeit to a more modest extent
than RNF4 (Figures 1C, 4C, and 4D). These results show thatCell Reports 16, 3388–3400, September 20, 2016 3391
Figure 3. RNF4-Mediated Stabilization Requires Binding and Ubiquitylation of Phosphorylated pSer62-c-Myc and pSer45-b-Catenin
(A) In-vitro-translated (IVT) labeled 35S-Met-Hairy (positive control) and 35S-Met-c-Myc bind to GST-RNF4, while 35S-Met-c-MycS62A binds weakly to GST-RNF4.
(B) Mock-treated, but not CIP-treated, 35S-Met-c-Myc binds to GST-RNF4 (CIP, calf intestinal phosphatase).
(C) Upper: RNF4 ubiquitylates c-Myc and to a lesser extent c-MycS62A in HEK293T cells. Cells were transfected with indicated plasmids, and His-Ubproteins
were recovered on Ni-NTA agarose, followed by western blot analysis with a c-Myc antibody. Lower: overall ubiquitylation determined using a a-Ub antibody.
Actin serves as loading control.
(D) Steady-state levels of endogenous b-catenin and RNF4 in extracts derived from MD-MB231 cells expressing shRNF4(C1) or control sc-shRNA.
(E) FLAG-b-catenin, but not FLAG-b-cateninS45A, is stabilized by RNF4 in HEK293T cells.
(F) IVT 35S-Met-b-catenin, but not 35S-Met b-cateninS45A, binds to GST-RNF4. In (A), (B), and (F) 5% input is shown, and lower gels are Coomassie staining of
the gel.
(G) Upper: RNF4 ubiquitylates b-catenin, but not b-cateninS45A. Ubiquitylated FLAG-b-catenin was detected using a-FLAG antibody. Lower: overall ubiquitylation
was determined by using a a-Ub antibody.RNF4’s ARM domain is required for binding to the phosphory-
lated substrates, and suggest that protein stabilization occurs
in the nucleus in the vicinity of or on chromatin.
Next, we asked how RNF4 ligase activity results in protein sta-
bilization. We hypothesized that RNF4 ligase activity may inhibit
substrate ubiquitylation and subsequent degradation, or is re-
quired for catalyzing polyubiquitin chains that are not involved
in targeting proteins for degradation. Indeed, high molecular
weight endogenous and exogenous c-MycUbiquitin conju-
gates were readily observed when ubiquitylation was monitored
in HEK293T cells expressing RNF4, but not RNF4C159A mutant
protein (even in the absence of proteasomal inhibitors; Figures
4E and 4F). Therefore, we assessed whether stabilization re-
quires the catalysis of polyubiquitin chains by using a mutant
ubiquitin that acts as a ‘‘chain terminator’’. In this mutant
ubiquitin (UbK0) all the internal Lys residues were replaced by
Arg (Ziv et al., 2011). Herein RNF4 was unable to stabilize and3392 Cell Reports 16, 3388–3400, September 20, 2016ubiquitylate c-Myc in HA-UbK0-expressing cells (Figures 4G,
4H, 5A, S4C, and S4D). Moreover, we found that RNF4-depen-
dent stabilization of pSer62-c-Myc and p-Ser45 b-catenin in-
volves the catalysis of unusual ubiquitin chains with internal link-
age of K11, K33 of ubiquitin, but not K6, K27, K29, K48, or K63,
(Figure 4G, quantitated in Figures 4H, 5A, S4C, and S4D).
Remarkably, using ubiquitin mutants that each contain only a
single Lys residue (K*), we found that only co-expression of
K11* and K33* was sufficient for stabilization and ubiquitylation
of both c-Myc (Figures 4I and 5B), and b-catenin (Figures 4J
and 5C). These observations fit well with our report that the
Drosophila ortholog of RNF4, Dgrn, catalyzes mixed polyubiqui-
tin chains (Abed et al., 2011).
The stabilizing effect of RNF4 may also be a result of compro-
mising the machineries involved in the physiological degradation
of c-Myc and b-catenin, which are targeted for proteasomal
degradation by the SCF-ubiquitin ligase complexes SCFFbw7
Figure 4. RNF4-Dependent Stabilization Requires the ARM Domain and K179 within RNF4 as well as the Catalysis of K11/ K33-Containing
Polyubiquitin Chains
(A) Schematic diagram of hRNF4 (not to scale): SIM, SUMO-interactingmotif; ARM, arginine-richmotif; RING, really interesting gene; NTR, nucleosome-targeting
region.
(B) Left: in-vitro-translated (IVT) c-Myc binds to GST-RNF4, but not to GST-RNF4DARM. Right: protein levels of the GST-fusion proteins used as determined by
Coomassie blue staining.
(C and D) b-catenin (C) and c-Myc (D) luciferase reporter assays in HEK293T cells transfected with the indicated plasmids. Data shown are mean ± SE from three
independent experiments performed in triplicates. Lower: western blot analyses of steady-state levels of b-catenin, c-Myc, and RNF4 in representative extracts.
Actin serves as loading control.
(E) Endogenous c-Myc is ubiquitylated by RNF4, but not by the RING mutant RNF4C159A. Upper: HEK293T cells were transfected with the indicated plasmids.
Endogenous c-Myc was immunoprecipitated using a-c-Myc antibody (#sc789), and ubiquitylated c-Myc was detected using a-Ub antibody. Lower: overall
ubiquitylation determined using a a-Ub antibody.
(F) Expression of RNF4, but not of RNF4C159A, results in c-Myc ubiquitylation. The proteasome inhibitor MG132 was added as indicated, c-MycUb conjugates
were recovered using Ni-NTA resin and detected using a-c-Myc antibody (9E10).
(G and H) c-Myc stabilization requires RNF4-dependent catalysis of K11/K33 containing polyubiquitin chains. Western blot analysis of the indicated proteins
in extracts derived from HEK293T cells transfected with c-Myc and GFP or RNF4 expression vectors. Where indicated, cells were transfected with HA-tagged
wild-type ubiquitin or mutants where a specific Lys was replaced by Arg (K#R). K0 is an ubiquitin molecule in which all internal Lys residues were replaced with
Arg. c-Myc protein level was determined using indicated antibodies (G). Quantitation of the effect of ubiquitin mutants on RNF4-dependent c-Myc stabilization
using 9E10 antibody (Data shown are mean ± SE, n=6) (H).
(I and J) Steady-state protein levels of c-Myc (I), b-catenin (J), and RNF4 in cells transfectedwith the indicated ubiquitinmutants. UbK11* and UbK33* are ubiquitin
molecules that contain a single lysine where all other lysine residues are replaced with Arg. Fold: relative change in c-Myc and b-catenin protein levels.and SCFbTRCP, respectively (Welcker et al., 2004; Winston et al.,
1999). We asked whether RNF4 compromises the activity of
these ligases. Transfection of SCFFbw7 in HEK293T cells
decreased c-Myc protein levels 3-fold (Figure 5D). Co-expres-
sion of RNF4 and SCFFbw7 also reduced c-Myc levels 3-fold
compared to expression of RNF4 alone. Thus, RNF4 does notinterfere with SCFFbw7-dependent c-Myc degradation. Similarly,
an established assay for SCFbTRCP ligase activity is the TNFa-in-
duced degradation of the cytoplasmic inhibitor of NF-kB, p-IkB
(Yaron et al., 1998). RNF4 neither polyubiquitylated nor stabilized
IkBa, and had no effect on TNFa-induced NF-kB transcription
activation (Figures S3A–S3C). We also found that RNF4 doesCell Reports 16, 3388–3400, September 20, 2016 3393
Figure 5. K11 and K33 within Ubiquitin Are Required for RNF4-Dependent Ubiquitylation, and RNF4 Does Not Inhibit c-Myc Degradation by
Fbw7a
(A–F) Western blot analyses of extracts derived from HEK293T cells transfected with the indicated vectors.
(A) Upper: c-Myc polyubiquitylation by RNF4 requires polyubiquitylation and K33 Lys residue within ubiquitin. Lower panel: Overall ubiquitylation determined
using a a-Ub antibody.
(B and C) Co-expression of K11* and K33* within ubiquitin is sufficient for RNF4-dependent ubiquitylation. Upper: Cells were transfected with plasmids coding for
c-myc (B) or b-catenin (C), andwhere indicatedwith RNF4 aswell as wild-type ubiquitin or ubiquitin mutants that harbor single Lys residues (UbK11* andUbK33*).
Lower: Overall ubiquitylation determined using a a-Ub antibody.
(D) Expression of SCFFbw7 reduces c-Myc protein levels in control and RNF4-expressing cells.
(E and F) RNF4 stabilizes and ubiquitylate PGC1a. (E) CHX-chase experiment (0–60 min) in cells expressing plasmids coding for PGC1a, GFP, RNF4, or
RNF4C159A, followed by western blot analysis of PGC1a and actin (loading control). (F) PGC1a is ubiquitylated by RNF4. Cells were transfected with HA-ubiquitin
and the indicated plasmids. Ubiquitylation was detected similar to that described in (A).not target other components of the SCF complex for degrada-
tion, and that limiting E2 levels were not the cause of RNF4-
dependent stabilization. Moreover, proteasome activity was
identical in RNF4 or control expressing cells (Figures S3D-G).
Thus, the stabilizing effect of RNF4 is direct, and is not due to
an impact on the machinery that mediates the turnover of these
proteins.
Interestingly, RNF4 stabilizes other transcription factors that
are phosphorylated by mitogenic kinases and degraded by3394 Cell Reports 16, 3388–3400, September 20, 2016SCFFbW7. These include, PGC1a (peroxisome proliferator-acti-
vated receptor gamma co-activator 1a), c-Jun, and notch
intra-cellular domain (NICD) protein, which were all stabilized
and ubiquitylated by exogenous RNF4, but not RNF4-mutants
(Figures 5E, 5F, 6A, 6C, S2G, S4E, and S4F). For example,
NICD, the cleaved intracellular domain of Notch, acts as tran-
scriptional co-activator for Notch targets (Kopan, 2012). Flag-
NICD protein levels were increased following co-expression of
RNF4 in MK4 cells (Figure 6A). These cells express endogenous
Figure 6. RNF4 Stabilizes Short-Lived Oncoproteins and Enhances Notch-Dependent Transcriptional Activation Independent of De Novo
SUMOylation
(A) 35S-Met pulse chase analysis of FLAG-NICD in MK4 cells expressing indicated plasmids, followed by a-Flag-IP.
(B) RNF4, but not RNF4C159A, enhances Delta-dependent Notch-induced activation of the TP1-Luciferase canonical Notch reporter in a co-culture assay. Data
shown aremean ±SE from three independent experiments. MK4 cells were co-cultured either with CHO-IRES-GFP (control, black bars) or CHO-Delta-IRES-GFP
(white bars), as indicated.
(C) Left: RNF4, but not RNF4DARM, stabilizes p-c-Jun. Right: c-Jun and p-c-Jun protein levels in MDA-MB231 cells expressing shRNF4(C1) or sc-shRNA.
(D–G) Protein levels of HA-c-Myc (D), FLAG- b-catenin (E), FLAG-NICD (F), His-c-Jun (G), and endogenous SAE2 in MDA-MB231shSAE2Dox cells. Cells were
transfected with indicated plasmids in the presence or absence of 200 ng/ml doxycycline (Dox). Actin serves as loading control.
(H) Western blot analyses of endogenous proteins in MDA-MB231shSAE2Dox co-expressing lenti-viral Dox-induced RNF4.
(I and J) Proposed model for RNF4-dependent enhancement of Wnt (I) and Notch (J) signaling. Genes are depicted in italic, and proteins are embedded in ovals.
℗ indicates phosphorylation.Notch receptor, and can be activated by Delta to enhance
expression of a Notch reporter. We observed that RNF4, but
not RNF4C159A, enhanced Delta-dependent transcriptional acti-
vation of the reporter, whereas the basal activity of the reporter
was not affected (Figure 6B). These results indicate that NICD
generated by ligand-dependent Notch cleavage is the target
of RNF4.
Protein Stabilization by RNF4 Is SUMOylation
Independent
RNF4 recognizes SUMOylated substrates by its SIM motifs.
However, in yeast the recognition of the non-SUMOylated pro-
tein, MATa repressor, was described (Xie et al., 2010). Therefore,
we determined whether RNF4-dependent stabilization require
SUMOylation. We used a breast cancer cell line that expresses
shRNA inactivating SAE2, a subunit of the SUMO-activatingenzyme E1, in a doxycycline (Dox)-inducible manner inhibiting
de-novo SUMOylation (MDA-MB-231DoxSAE2shRNA cells; Fig-
ure 6D) (Kessler et al., 2012). Remarkably, addition of Dox
decreased SAE2 levels, and reduced de-novo SUMOylation,
but did not affect RNF4-dependent stabilization of c-Myc, b-cat-
enin, NICD, and c-Jun at steady state or c-Myc in pulse-chase
experiments (Figures 6D–6G, S5A, and S5B).While SAE2 knock-
down reduced the basal level of b-catenin (Figure 6E), the ability
of RNF4 to stabilize b-catenin, and enhance b-catenin-depen-
dent transcriptional activation was similar in the presence or
absence of SAE2 (Figures 6E and S5C). Nevertheless, and as ex-
pected, in the presence of functional SAE2 RNF4 expression
resulted in reduction in the cellular pool of poly-SUMOylated
proteins (Figure S5D). Moreover, we tested whether expression
of RNF4 in this context affects the stability of the endogenous
proteins studied above. We infected MDA-MB-231DoxSAE2shRNACell Reports 16, 3388–3400, September 20, 2016 3395
cells with lenti-viral vectors coding for Dox-induced expres-
sion of RNF4. Thus, following Dox addition these cells inacti-
vate SAE2 and concomitantly express RNF4 (Figure 6H). We
found that Dox addition resulted in higher levels of all these
endogenous proteins including p-c-Myc, and p-c-Jun. Thus,
RNF4-dependent protein stabilization and enhancement of
transcriptional activation are independent of de-novo covalent
SUMOylation.
RNF4 Is Essential for Cancer Cells and Potentiates
Tumor Cell Properties, and Its Levels Are Elevated in
Distinct Subsets of Human Cancers
Since RNF4 stabilizes oncoproteins and potentiates their activ-
ity, we examined the effects of RNF4 inhibition and expression
on cancer cell properties. Expression of constitutive shRNF4
inhibited proliferation of MDA-MB-231 cells, a triple-negative
breast cancer cell line that is Myc-dependent (Figure 7A; Kessler
et al., 2012). RNF4 knockdown also resulted in extensive cell
death: 47% apoptotic cells were observed in RNF4-targeted
cells compared to 6.8% in control cells (Figures S6A-D). Like-
wise, downregulation of RNF4 inhibited colony formation of
these cells in soft agar, and similar results were observed in mel-
anoma and osteosarcoma cells (Figures 7B and 7C; data not
shown). These effects were not augmented when SUMOylation
was co-inhibited (i.e., conditional SAE2 knockdown). Further-
more, downregulation of SAE2 alone did not result in cell death
or impaired colony formation (Figures 7B and S6B). Remarkably,
expression of c-Myc partially restored colony growth in soft agar
of RNF4-knockdown cells (Figures 7B and 7C). These data fit
well with our observation that RNF4 is required to maintain the
level of c-Myc protein in MDA-MB231 cells (Figure 2C), and en-
hances its transcriptional activity (Figures 4D and S2H), suggest-
ing that the essential role of RNF4 in these cells is mediated, in
part, by its effect on c-Myc.
Moreover, RNF4 potentiates the tumorous properties of can-
cer cells. Dox-induced expression of RNF4 but not RNF4DARM
or RNF4C159A enhanced sphere formation of MCF7 breast can-
cer cells that are less aggressive cancer cells in comparison
with MDA-MB231 (Figures 7D). Remarkably, we observed that
high levels of RNF4 mRNA correlate with poorer survival in a
cohort of systemically untreated ‘‘type A,’’ but not ‘‘type B,’’
luminal estrogen positive breast cancer patients (Figure 7E;
data not shown).
The ability of RNF4 to enhance tumorigenesis in culture was
not limited to breast cancer cells but was also observed in
SW480 colon cancer cells. Conditional expression of RNF4 but
not RNF4DARM or RNF4C159A in SW480 cells increased the num-
ber and size of spheres (Figures 7F, S6E–S6H’, and S6I). Since
RNF4 enhances sphere formation of colon cancer cells we deter-
mined whether RNF4 protein is overexpressed in human-derived
specimens of intestinal tumorigenesis. We analyzed 99 patient-
derived colon biopsies of which 33 correspond to normal
mucosa, 32 to benign adenomas, 1 to a carcinoma in situ, and
33 to malignant adenocarcinomas (see examples in Figures
7G–7J’). Elevated RNF4 protein levels were only observed in
1 out of 65 benign or normal colon biopsies. However, 29% (9/
34) of adenocarcinomas exhibited significantly elevated RNF4
protein levels (p < 0.001). Interestingly, in the single case of an3396 Cell Reports 16, 3388–3400, September 20, 2016in situ carcinoma the elevated RNF4 protein level was confined
to themalignant area and not found in the benign tissue (Figure 7I
and 7I’). Thus, elevated RNF4 levels in a subset of malignant tu-
mors suggest that RNF4 overexpression may define specific
sub-groups of human breast and colon cancer.
DISCUSSION
Modifications by ubiquitin and ubiquitin-like proteins are inti-
mately linked to tumorigenesis (Popovic et al., 2014). In many
cases ubiquitylation targets oncogenes for proteasomal degra-
dation (Ciechanover et al., 1991). In contrast, RNF4-dependent
ubiquitylation stabilizes a subgroup of oncogenic transcription
factors. RNF4 directly recognizes and stabilizes its targets, and
phosphorylation, but not de-novo-SUMOylation of these targets
is a prerequisite for substrate recognition and stabilization. While
phosphorylation of proteins is often transient (Hunter, 1995),
RNF4-dependent stabilization of b-catenin, c-Myc, and NICD
persists for hours. Hence, RNF4 translates short-term phosphor-
ylation signals into long-lasting effects, augmenting the tran-
scriptional output of Wnt and Notch pathways. This prolonged
effect establishes a feed-forward mechanism that enhances
oncogenic activity (Figures 6I and 6J). In accordance, RNF4 en-
hances cancer cell survival, and RNF4 levels are elevated in a
subset of human colorectal and breast tumors correlating with
poor outcome for the latter.
Mechanisms of RNF4-Dependent Oncogene
Stabilization
STUbL proteins like RNF4 recognize SUMOylated substrates
(Sriramachandran and Dohmen, 2014). Remarkably, we find
that RNF4 also binds and stabilizes its substrates in a manner
that depends on phosphorylation but not SUMOylation. RNF4
substrates are nuclear transcriptional regulators that enhance
G1-S transition and promote proliferation and tumorigenesis.
They are activated by phosphorylation via kinases such as
Mapk, Cdk2, p38, or CKI. Yet, the underlining mechanisms
involved had not been fully identified. These phosphorylations
are essential for RNF4 binding, ubiquitylation and stabilization.
Another example in which RNF4 recognizes a phosphorylated
protein is KAP1 (Kuo et al., 2014). Yet KAP1 is recognized
when it is phosphorylated and SUMOylated via both the ARM
and SIM domains leading to its degradation. Thus, recognition
by ARM alone and the dual recognition by both the ARM and
SIM motifs results in ubiquitylation, but nonetheless have oppo-
site outcomes for protein stability.
The question arises as to how these opposite outcomes of
protein stability are achieved. We found that RNF4-dependent
protein stabilization of c-Myc and b-catenin requires the catal-
ysis of polyubiquitin chains linked at position UbK11 and
UbK33, which are associated with immunity, cell-cycle progres-
sion and protein trafficking, (Iwai, 2014, Wickliffe et al., 2011,
Yuan et al., 2014). However, in RNF4-dependent degradation
of SUMOylated proteins, mixed SUMO-ubiquitin chains, as
well as UbK48-linked chains, are formed. This ability to generate
chains with different types of internal linkage may stem
from distinct interactions of RNF4 with several E2 enzymes
(Ha¨kli et al., 2004; Guzzo et al., 2012). We suggest that
Figure 7. RNF4 Is Essential for Survival and Potentiates Tumorous Phenotype of Cancer Cells and Its mRNA and Protein Levels Are Elevated
in Subtypes of Breast and Colon Adenocarcinoma
(A)MTT proliferation assay inMDA-MB231shSAE2Dox cells infectedwith indicated shRNAs, where Dox-induced the expression of SAE2 shRNA (Dox+). Data shown
are mean ± SE from three independent experiments.
(B and C) RNF4, but not SAE2, is required for colony formation in soft agar of MDA-MB231shSAE2Dox cells. (B) Representative colony formation assays in soft agar.
Dox (Dox+) activates shSAE2, inactivating SAE2. Co-expression of c-Myc along with RNF4 inactivation partially restores the ability of the cells to form colonies.
Scale bar represents 3.5 mm. (C) Quantification of colony formation assays. Data shown are mean ± SE from three independent experiments (n = 3).
(D) Sphere formation in non-adherent conditions of MCF7 breast cancer cells is enhanced by expression of Dox-induced RNF4, but not in control, RNF4DARM, or
RNF4C159A. Data shown are mean ± SE from three independent experiments.
(E) Kaplan-Meier survival curves of ER-positive ‘‘type A’’ luminal breast cancer patients with low (black) or high RNF4 (red) mRNA levels (p = 0.0068, n = 324).
(F) Left: sphere formation in non-adherent conditions of SW480 colon cancer cells is enhanced by expression of Dox-induced RNF4, but not in control, RNF4DARM,
or RNF4C159A. Data shown are mean ± SE from three independent experiments performed in triplicates. Right: microscopic image of representative spheres.
Scale bar represents 50 mm.
(G–J’) RNF4 protein levels in patient-derived colon biopsies. (G–J) H&E staining. (G’–J’) Immunostaining with a-RNF4. (G–G’) Normal colonic mucosa. (H–H’)
Colonic adenoma. (I and I’) High-grade colonic adenoma with in situ carcinoma (CIS). Note the elevated RNF4 levels left to the dotted line, where the cancerous
part of the lesion. (J–J’) Adenocarcinoma of the colon. The dotted black square is shown in the inset. (J’). Scale bar represents 10 mm.the internal linkage of the ubiquitin chain may well determine
whether RNF4-dependent ubiquitylation promotes protein de-
gradation or stabilization.
Regulation of Wnt Signaling and c-Myc by Ubiquitylation
and SUMOylation
Ubiquitylation is known to regulate Wnt signaling beyond the
degradation of b-catenin by SCF bTRCP. The ubiquitin ligasesRNF43, and RNF14 modulate Wnt pathway activity but do not
alter b-catenin stability or bind to b-catenin directly (Koo et al.,
2012; Wu et al., 2013). A third ligase, EDD, stabilizes b-catenin
but requires phosphorylation of Ser33 of b-catenin; the onco-
genic b-cateninS33A mutant is unaffected by EDD (Hay-Koren
et al., 2011). However, RNF4 enhanced b-cateninS33A activity,
indicating that EDD and RNF4 target different pools of b-catenin
modified by distinct mechanisms. Moreover, the observationsCell Reports 16, 3388–3400, September 20, 2016 3397
that RNF4 enhances the activity of cancerous-related b-catenin
mutants may offer a strategy to target cancers where the degra-
dation of b-catenin is compromised.
Similar to ubiquitylation, SUMOylation regulates the Wnt
pathway. We show here that targeting the SUMO E1 subunit
SAE2 reduced b-catenin protein level and impaired b-catenin
transcriptional activity, consistent with a previous report (Choi
et al., 2011). However, RNF4-dependent protein stabilization as
well as its transcriptional and biological activities were not
affected by targeting SAE2 and inhibition of SUMOylation.
SUMOylation was also reported to target c-Myc for degradation,
and to maintain a c-Myc signature in MDA-MB-231 cells overex-
pressing MycER (Gonza´lez-Prieto et al., 2015; Kessler et al.,
2012). Thus, differences in c-Myc levels and the biological context
might account for these distinct cellular responses. Furthermore,
while RNF4 targets several nuclear proteins, c-Myc is an impor-
tant target of RNF4 in MDA-MB-231 cells. Yet, the ability of
RNF4 to potentiate c-Myc activity may involve other aspects
beyond an impact onMyc stability. For example, RNF4 enhances
Myc transcriptional activity to a greater extent than an experi-
mental increase in c-Myc protein to a similar level, and the delete-
rious effects of RNF4 knockdown in MDA-MB-231 cells can
partially, but not fully, be rescued by c-Myc overexpression.
RNF4 Forms a Feed-Forward Loop that Enhances Wnt
and Notch Signaling
In response to Wnt ligands, b-catenin directly induces the
expression of c-Myc. c-Myc then induces the expression of the
RNF4 gene, which is a direct c-Myc target, and is also induced
by Wnt/b-catenin (Reymann and Borlak, 2008; Dutta-Simmons
et al., 2009). Once induced, RNF4 enhances Wnt signaling in
two molecular ways. First, it inactivates the Groucho/TLE co-
repressor alleviating repression of Wnt targets. Second, it stabi-
lizes the key co-activator of the pathway b-catenin and its target
c-Myc protein. Thus, both mechanisms: RNF4-mediated stabili-
zation of b-catenin and c-Myc, and the suppression of Groucho/
TLE activity enhance and prolong Wnt signaling (model in
Figure 6I).
Similarly, RNF4 establishes a feed-forward loop potentiating
Notch signaling. An important and direct target of Notch/NICD
is again c-Myc (Weng et al., 2006). Subsequently, RNF4 stabi-
lizes NICD and c-Myc, and enhances Notch-dependent tran-
scriptional activity (model in Figure 6J).
These feed-forward loops established by RNF4 are important
in development. For example, the phenotype observed in the
Drosophila wing of a Notch gain-of-function mutant is sup-
pressed by reducing the dose of Dgrn (Barry et al., 2011). Like-
wise, this mechanism may also be important to maintain the
malignant phenotypes of intestinal tumors and T cell leukemia
where c-Myc collaborates withWnt andNotch signaling, respec-
tively (Sansom et al., 2007; Weng et al., 2006).
A Vital Role for RNF4 in Cancer
RNF4 is essential for the proliferation and survival of aggressive
cancer cells and its expression potentiates tumorigenesis in
culture. Supporting these observations, we were not able to
generate viable null RNF4 homozygous colon cancer cells by
CRISPER/CAS9 genome editing. RNF4 is not frequently mutated3398 Cell Reports 16, 3388–3400, September 20, 2016in breast and colon cancer (http://cancer.sanger.ac.uk/cosmic),
and RNF4 mRNA level is elevated in only 3% of colon cancer
specimens of the Sanger collection. However, high levels of
RNF4 mRNA correlate with poor outcome of ER+ luminal ‘‘type
A’’ breast cancer patients. Moreover, RNF4 protein levels are
elevated in 30% of colon carcinoma samples, but not in normal
human intestinal tissues or benign adenomas. The upregulation
of RNF4 mRNA and protein in cancer is in agreement with
RNF4’s ability to stabilize and potentiate the transcriptional activ-
ity of oncogenes like c-Myc, b-catenin, and c-Jun. Thus, in
defined epithelial cancers, RNF4 fits into a class of genes collec-
tively termed ‘non-oncogene addiction’ genes (NOA; Luo et al.,
2009). These act often in a tissue- and cancer-specific manner.
They encode proteins that alone are not tumorigenic, but are
essential to maintain the tumorigenic phenotypes. ‘‘NOA’’ genes
are less significant for the viability of normal cells, making them
attractive for cancer therapy. Future studies will determine
whether RNF4-positive tumors define a distinct subset of tumors.
EXPERIMENTAL PROCEDURES
Materials
Full list of antibodies, plasmids, and primers used in this study can be found in
the Supplemental Information.
Methods
Cell Lines
Human HEK293T, MDA-1833, MDA-MB231, HCT116, SW620, and SW480
cells were obtained from the American Type Culture Collection. MDA-
MB231shSAE2Dox cells were a kind gift of Thomas F. Westbrook (Baylor College
of Medicine).
shRNA Design, Production, and Targeting
Generation of constitutive pLKO-based shRNF4 (C1, C2) scrambled (sc-
shRNA; control) Dox-induced expression of pInducer-RNF4 system (control,
RNF4, RNF4C159A, RNF4DARM), and conditional miR-30-based RNF4 knock-
down (shRNF4-1Dox, ShRNF4-2Dox, and Renilla control) are described in the
Supplemental Experimental Procedures.
qPCR Analysis
qPCR analysis was performed as described in Heuberger et al. (2014).
Flow Cytometry, Cell-Cycle Analysis, MTT Proliferation, Cancer
Sphere Assay, and Colony Formation in Soft Agar
Cell-cycle and apoptosis analyses was performed using the FACS-Calibur (BD
Biosciences) system and FlowJo software (Tree Star). MTT assays were per-
formed using MTT solution (Sigma-Aldrich) and processed according to the
manufacturer’s instructions and Stat Fax 2100 ELISA reader. Colony and
sphere formation were performed similar to that described in Staller et al.
(2001) and Fang et al. (2016).
Protein Stability Assays
Protein stability in steady state and dynamic CHX chase and 35S-Met pulse/
chase experiments were performed as previously described (Abed et al.,
2011; Trausch-Azar et al., 2015). Pulse labeling was 10 min for c-Myc
and 30 min for NICD at 37C. Immunoprecipitation of c-Myc and FLAG-
NICD proteins was performed using a-c-Myc (N262, 1:50) and a-Flag
(1:200), respectively.
Kinase inhibitors were added for 4 hr. Conditional shRNA expression was
induced using 200 ng/ml doxycycline for 36 hr before cell harvesting. Cells
were lysed in RIPA buffer supplementedwith protease and phosphatase inhib-
itors, and lysates were resolved over SDS-PAGE. Proteins were identified us-
ing indicated antibodies and chemiluminescence (Image-Quant LAS4000).
TNFa-Induced IkBa Degradation
3 3 105 cells/ml HEK293T cells were seeded in 6-well plates and transfected
the next day with indicated vectors. 24 hr post-transfection, 40 ng/ml TNFa
was added to induce IkBa degradation. Protein levels were determined by
western blot analysis.
Wnt and Myc Luciferase Reporter Assays and Notch Co-culture
Reporter Assays
Reporter assays were performed as previously described in Abed et al. (2011).
Where indicated, LiCl was added for 12 hr at a final concentration of 15 mM to
activate the TOP-reporter. TNFawas added for 6 hr at 2.5 ng/ml to activate the
NFkB reporter. For testing RNF4 on Notch-dependent activation, co-culture
assays were performed as in Ong et al. (2008).
In Vitro GST-Binding Assays
Binding assays were performed as previously described (Abed et al., 2011) by
using bacterial expressed purified and immobilized GST, GST-RNF4, GST-
RNF4DARM, GST-Dgrn, and GST-RNF4DSIM proteins, as well as the indicated
in-vitro-translated proteins. For substrate de-phosphorylation, the indicated
proteins were pre-incubated with CIP or buffer for 20 min.
Ubiquitylation and SUMOylation in Cells
Ubiquitylation and SUMOylation were performed as previously described
(Abed et al., 2011; Trausch-Azar et al., 2015). Where indicated, cells were incu-
bated with 40 mM MG132 for 4 hr and subjected to hot lysis, followed by im-
mune precipitation. Where His-Ub was used, cells were lysed in 1 ml guani-
dine-hydrochloride buffer, followed by binding to Ni-NTA beads (QIAGEN) in
the presence of 20 mM imidazole. Ubiquitylated and SUMOylated proteins
were visualized via SDS-PAGE gels followed by western blotting.
Pathology
Biopsies were from the Institute of Pathology, RAMBAM Healthcare Haifa.
Paraffin-embedded sections were prepared and immunostained with indi-
cated antibodies using BenchMark XT system. A certified GI pathologist
confirmed diagnosis of each case (under the Helsinki committee approval
number 0239-12-RMB).
Survival Analyses of Breast Cancer Patients
Analyses of systemically-untreated cohort of breast cancer patients including
Kaplan-Mayer survival curves were performed using kmplot.com (http://
kmplot.com/analysis/index.php?p=service&start=1). n = 324, p < 0.068
HR = 1.66 (1.15-2.4), and the following criteria: ER+, Type: ‘‘luminal, A’’ sys-
temically untreated patients.
Digital Image Processing
Original ECL-were captured using LAS4000. Original TIFF files were trans-
ferred to Photoshop software. If required, using ‘‘levels’’ option at the
Photoshop menu the entire file was adjusted to point to subtle differences.
Subsequently, the relevant part of the image was copied to CanvasX graphic
program to generate the illustration. At this stage only proportional adjust-
ments in scale were made. No other processing were performed. Files were
saved as high resolution CanvasX TIFF file. Where indicated signal quantifi-
cation was performed using Image-Quant.
Statistical Analysis
Statistical analysis, SEM and t test comparisons were performed using Graph-
Pad Prism and ANOVA software. In all experiments, significance is as follows:
**** p < 0.0001, *** p < 0.001, ** p < 0.05, * p < 0.01.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.08.024.
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